Damsky, William

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 308

KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements

Zhang, S.-M., Cai, W. L., Liu, X., Thakral, D., Luo, J., Chan, L. H., McGeary, M. K., Song, E., Blenman, K. R. M., Micevic, G., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersEpigenetics and DNA Methylation

Cited by 272

UV‐induced somatic mutations elicit a functional T cell response in the YUMMER 1.7 mouse melanoma model

Wang, J., Perry, C. J., Meeth, K., Thakral, D., Damsky, W., Micevic, G., Kaech, S., Blenman, K., & Bosenberg, M. (2017) · Pigment Cell & Melanoma Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 199

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma

Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 199

mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation

Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D. P., Santhanakrishnan, M., Erdelyi, I., Platt, J. T., Huang, L., Theodosakis, N., et al. (2015) · Cancer Cell

Melanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 142

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors

Damsky, W., Jilaveanu, L., Turner, N., Perry, C., Zito, C., Tomayko, M., Leventhal, J., Herold, K., Meffre, E., Bosenberg, M., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 78